United States Patent Office Agrees With PureLine Against Nalco Patent

United States Patent Office Agrees With PureLine Against Nalco Patent

Press Release (ePRNews.com) - BENSENVILLE, Ill. - Aug 31, 2020 - PureLine Treatment Systems, LLC recently sought reexamination of United States Patent No. 6,790,427, currently owned by Ecolab USA, Inc., Nalco US 1, LLC and Nalco Company, which had been asserted by Ecolab in Civil Action No. 19cv4523, filed July 3, 2019 (U.S.D.C., N.D. Ill., dismissed). The United States Patent Office agreed with PureLine, finding PureLine had successfully raised a substantial new question of the patentability of the Ecolab patent. The patent will now proceed to full reexamination by the United States Patent Office.

About PureLine, Inc.

​PureLine is an expert in the manufacture, generation, and application of chlorine dioxide. PureLine specializes in designing and implementing chlorine dioxide solutions utilizing our broad line of proven ClO2 generators and precursor chemicals to control and inhibit the growth of mold, mildew, and odor-causing bacteria. PureLine’s EPA registered ClO2 products include PureVistaTM, Pure 3000TM, and PureCide® E. In locations across the nation and around the world, PureLine’s patented and proven high-purity chlorine dioxide generation equipment and expert services are enhancing the reliability, efficiency, and cost-effectiveness of decontamination process.

Media Contact:
Alex Whitmore
Email: alex.whitmore@pureline.com

Source : PureLine Treatment Systems, LLC
SHARE :  

CATEGORIES : Chemicals

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login

DISCLAIMER

If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.